Laurion Capital Management LP Reduces Position in Magenta Therapeutics Inc (MGTA)

Laurion Capital Management LP lowered its holdings in Magenta Therapeutics Inc (NASDAQ:MGTA) by 18.8% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 284,124 shares of the company’s stock after selling 65,876 shares during the period. Laurion Capital Management LP owned approximately 0.86% of Magenta Therapeutics worth $3,412,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Casdin Capital LLC acquired a new position in shares of Magenta Therapeutics in the second quarter valued at approximately $27,484,000. FIL Ltd grew its holdings in shares of Magenta Therapeutics by 15.8% in the third quarter. FIL Ltd now owns 956,784 shares of the company’s stock valued at $11,491,000 after purchasing an additional 130,312 shares in the last quarter. Opaleye Management Inc. acquired a new position in shares of Magenta Therapeutics in the second quarter valued at approximately $7,425,000. Harvard Management Co. Inc. acquired a new position in shares of Magenta Therapeutics in the second quarter valued at approximately $4,490,000. Finally, Voya Investment Management LLC acquired a new position in shares of Magenta Therapeutics in the second quarter valued at approximately $3,387,000. Hedge funds and other institutional investors own 30.79% of the company’s stock.

Shares of Magenta Therapeutics stock opened at $7.83 on Friday. Magenta Therapeutics Inc has a 52-week low of $6.10 and a 52-week high of $16.33.

Magenta Therapeutics (NASDAQ:MGTA) last issued its quarterly earnings results on Thursday, November 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.18. On average, equities analysts expect that Magenta Therapeutics Inc will post -3.19 EPS for the current fiscal year.

Separately, Zacks Investment Research upgraded shares of Magenta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 29th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Magenta Therapeutics presently has an average rating of “Buy” and a consensus price target of $19.33.

ILLEGAL ACTIVITY WARNING: “Laurion Capital Management LP Reduces Position in Magenta Therapeutics Inc (MGTA)” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/12/08/laurion-capital-management-lp-reduces-position-in-magenta-therapeutics-inc-mgta.html.

About Magenta Therapeutics

Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.

Read More: What are the reasons investors use put options?

Want to see what other hedge funds are holding MGTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Magenta Therapeutics Inc (NASDAQ:MGTA).

Institutional Ownership by Quarter for Magenta Therapeutics (NASDAQ:MGTA)

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply